Venture capital investing involves substantial risk, including risk of loss of all capital invested
If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing in late 2026, MHRA approval in late 2027 to mid-2028, and NHS access through NICE from 2029 at the earliest
Key administration details: Subcutaneous injection, once weekly Reconstitute with bacteriostatic water following concentration calculations Use our peptide reconstitution calculator for exact water volumes Store reconstituted solution in refrigerator, see peptide refrigeration guidelines Typical vial sizes: 5 mg or 10 mg (varies by supplier) Use insulin syringes for accurate dosing The reconstitution step adds complexity that brand-name tirzepatide pens avoid entirely
Retatrutide is designed to support appetite control, improved metabolic regulation, and sustained weight management by acting on multiple hormone pathways involved in hunger and energy balance
What to Do If You Suspect Pancreatitis Immediate action is essential if pancreatitis is suspected during weight loss injection therapy
